Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arbutus Biopharma Corp 701 VETERANS CIRCLE WARMINSTER PA 18974 USA

www.arbutusbio.com Employees: 44 P: 267-469-0914 F: 267-282-0411

Sector:

Medical

Description:

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.

Key Statistics

Overview:

Market Capitalization, $K 780,836
Enterprise Value, $K 744,506
Shares Outstanding, K 192,324
Float, K 153,282
% Float 79.70%
Short Interest, K 12,536
Short Float 6.52%
Days to Cover 8.63
Short Volume Ratio 0.36
% of Insider Shareholders 20.30%
% of Institutional Shareholders 43.79%

Financials:

Annual Sales, $ 6,170 K
Annual Net Income, $ -69,920 K
Last Quarter Sales, $ 530 K
Last Quarter Net Income, $ -7,740 K
EBIT, $ -46,800 K
EBITDA, $ -45,420 K

Growth:

1-Year Return 31.41%
3-Year Return 43.52%
5-Year Return 11.24%
5-Year Revenue Growth 2.66%
5-Year Earnings Growth 76.54%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.04 on 11/13/25
Next Earnings Date 03/26/26
Earnings Per Share ttm -0.23
EPS Growth vs. Prev Qtr -500.00%
EPS Growth vs. Prev Year 60.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 11/04/10

ABUS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -50.26%
Return-on-Assets % -37.65%
Profit Margin % -1,133.23%
Debt/Equity 0.00
Price/Sales 54.97
Price/Cash Flow N/A
Price/Book 10.07
Book Value/Share 0.40
Interest Coverage -498.43
60-Month Beta 0.70
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar